ReviewFrontiers in oncology2023
The multiple roles of C-type lectin receptors in cancer.
Review in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 10 citations in OpenAlex.
- The C-type lectin AcCTL5 fromVirulence · 2026Article
- Expression dynamics and antiviral role of chicken OASL during infectious bronchitis virus infection.Poultry science · 2026Article
- Circadian rhythm of dendritic cells directs the time-dependent efficacy of photodynamic therapy.Cell communication and signaling : CCS · 2026Article
- Engineering molecularly imprinted polymers for receptor-specific cancer therapeutics.Nanoscale · 2026Review
- One-Step Microfluidic Manufactured Fucose-Decorated Sweetosomes Choose the Time and the Road for Their Intracellular Journey to Cancer Treatment.Advanced healthcare materials · 2026Article
- CLEC18A interacts with sulfated glycosaminoglycans and controls clear cell renal cell carcinoma progression.The FEBS journal · 2026Article
- Nanoparticle Drug Delivery Systems: The Future Direction for the Treatment of Tumors.International journal of nanomedicine · 2026Review
- Transmembrane lectins in cancer immunity: emerging drivers of myeloid-mediated immunosuppression.Frontiers in immunology · 2026Review
- Innate Immune Signaling in Gliomas: Regulatory Mechanisms and Targeting Potential in Tumor Progression.Life (Basel, Switzerland) · 2025Review
- DC-SIGN (CD209)-mediated interactions between bacteria, lung cancer tissues, and macrophages promote cancer metastasis.Infectious agents and cancer · 2025Article
- The Role of Pattern Recognition Receptors in Epigenetic and Metabolic Reprogramming: Insights into Trained Immunity.Journal of inflammation research · 2025Review
- CLEC4D as a Novel Prognostic Marker Boosts the Proliferation and Migration of Gastric Cancer via the NF-κB/AKT Signaling Pathway.International journal of general medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
C-type lectin receptors are a family of immune response receptors that can bind with a broad repertoire of ligands. It can function as innative immune receptors to surveillance bacteria, fungi, and virus invasions. The expressions of C-type lectin receptors (CLRs) are found in different types of tumors. But the role of C-type lectin receptors in cancer is not fully elucidated. And the underlying mechanisms of CLRs in carcinogenesis and tumor development remained unknown. It is known that CLRs bind to the glycosylated antigen on the cancer cells, regulating cancer cell invasion, migration, and metastasis. Meanwhile, the recognition of tumor glycans by antigen-presenting cells can stimulate antitumor immune response and induce immune tolerance. Also, some types of CLRs can be used as diagnostic markers for tumor cells, suggesting that C-type lectin can function as a new tumor therapeutic target and potential biomarkers. Given the therapeutic potential of CLRs in tumor treatments and the emerging roles of CLR in the tumor hallmarks, the multiple roles of CLRs in cancer were summarized in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.